Therapeutic Treatment Of Wounds

• US 20110009332A1
• Filed: 06/10/2010
• Published: 01/13/2011
• Est. Priority Date: 07/09/2009
• Status: Abandoned Application

• Current Assignee: Southwest Research Institute
• Original Assignee: Southwest Research Institute
• Inventors: ROSSINI, Jorge Gianny
• Application Number:
  US12/813,217
• Publication Number:
  US 20110009332A1
• Time in Patent Office: Days
• US Class Current: 514/18.6
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 38/06 Tripeptides
• CPC Class Codes: A61K 38/07 Tetrapeptides
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

The present disclosure relates to compositions and methods for treating wounded skin and/or increasing the mechanical strength of wounded skin through the administration of an effective amount of a proteasome inhibitor to such wounded skin.

Claims

1. A method of treating wounded skin to control scarring, the method comprising:

administering an effective amount of a proteasome inhibitor to wounded skin of a subject.

2. The method of claim 1, wherein the proteasome inhibitor exhibits a half maximal inhibitory concentration (IC₅₀) for 20S proteasome in the range of 0.02 nM to 1,000 nM.

3. The method of claim 1, wherein the proteasome inhibitor comprises PS-1.

4. The method of claim 1, wherein the proteasome inhibitor comprises curcumin.

5. The method of claim 1, wherein the proteasome inhibitor comprises bortezomib.

6. The method of claim 1, wherein the proteasome inhibitor comprises MG-132.

7. The method of claim 1, wherein the composition is combined with a pharmaceutically acceptable carrier.

8. The method of claim 1, wherein wounded skin administered with said effective amount of said proteasome inhibitor exhibits a first tensile strength T₁ after 28 days and untreated wounded skin exhibits a second tensile strength T₂ after 28 days, wherein T₂*1.05≦

T₁.

9. The method of claim 1, wherein wounded skin administered with said effective amount of said proteasome inhibitor exhibits a first thickness t_i after four days and untreated wounded skin exhibits a second thickness t₂ after four days, wherein t₂*1.05≦

t₁.

10. The method of claim 1, wherein the subject is mammalian.

11. The method of claim 1, wherein the proteasome inhibitor is administered topically.

12. The method of claim 1, wherein administration is performed at intervals selected from the group consisting of one or more times a year, one or more times a month, one or more times a week and one or more times a day.

13. A method of increasing the tensile strength of wounded skin, the method comprising:

administering an effective amount of a proteasome inhibitor to wounded skin of a subject.

14. The method of claim 13, wherein the proteasome inhibitor exhibits a half maximal inhibitory concentration (IC₅₀) for 20S proteasome in the range of 0.02 nM to 1,000 nM.

15. The method of claim 13, wherein the proteasome inhibitor comprises PS-1.

16. The method of claim 13, wherein the proteasome inhibitor comprises curcumin.

17. The method of claim 13, wherein the proteasome inhibitor comprises bortezomib.

18. The method of claim 13, wherein the proteasome inhibitor comprises MG-132.

19. The method of claim 13, wherein the composition is combined with a pharmaceutically acceptable carrier.

20. The method of claim 13, wherein wounded skin administered with said effective amount of said proteasome inhibitor exhibits a first tensile strength T₁ after 28 days and untreated wounded skin exhibits a second tensile strength T₂ after 28 days, wherein T₂*1.05≦

T₁.

21. The method of claim 13, wherein wounded skin administered with said effective amount of said proteasome inhibitor exhibits a first thickness t_i after four days and untreated wounded skin exhibits a second thickness t₂ after four days, wherein t₂*1.05≦

t₁.

22. The method of claim 13, wherein the subject is mammalian.

23. The method of claim 13, wherein the proteasome inhibitor is administered topically.

24. The method of claim 13, wherein administration is performed at intervals selected from the group consisting of one or more times a year, one or more times a month, one or more times a week and one or more times a day.